Financials data is unavailable for this security.
View more
Year on year Argenica Therapeutics Ltd had net income fall 13.80% from a loss of 4.82m to a larger loss of 5.48m despite a 214.90% increase in revenues from 61.00k to 192.09k.
Gross margin | -- |
---|---|
Net profit margin | -2,852.56% |
Operating margin | -4,204.83% |
Return on assets | -42.28% |
---|---|
Return on equity | -50.70% |
Return on investment | -50.70% |
More ▼
Cash flow in AUDView more
In 2024, Argenica Therapeutics Ltd increased its cash reserves by 71.30%, or 6.62m. Cash Flow from Financing totalled 11.63m or 6,056.57% of revenues. In addition the company used 5.06m for operations while cash from investing totalled 50.00k.
Cash flow per share | -- |
---|---|
Price/Cash flow per share | -- |
Book value per share | 0.1128 |
---|---|
Tangible book value per share | 0.1128 |
More ▼
Balance sheet in AUDView more
Current ratio | 6.75 |
---|---|
Quick ratio | -- |
Total debt/total equity | 0.00 |
---|---|
Total debt/total capital | 0.00 |
More ▼